(Q35025965)

5 August 2017

1 reference

title

Unique design issues in clinical trials of patients with bipolar affective disorder (English)

1 reference

5 August 2017

1

Robert M Post

1 reference

5 August 2017

2

David A Luckenbaugh

1 reference

5 August 2017

publication date

1 January 2003

1 reference

Journal of Psychiatric Research

5 August 2017

published in

1 reference

5 August 2017

volume

37

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

61-73

1 reference

Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Antidepressant-induced mania and cycle acceleration: a controversy revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Refractoriness induced by lithium discontinuation despite adequate serum lithium levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

A comparison of observational studies and randomized, controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The efficacy of lamotrigine in rapid cycling and non–rapid cycling patients with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Antiepileptic drugs, clinical trials, and the marketplace

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The crossover experiment for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Some Methods for Strengthening the Common χ 2 Tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Randomized, controlled trials, observational studies, and the hierarchy of research designs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

An analysis-of-variance model for the intrasubject replication design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Exactly what does the Hamilton Depression Rating Scale measure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Relapse and impairment in bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Evidence of chaotic mood variation in bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

On clinical trials in psychiatry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Methodologic issues in maintenance therapy clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The epidemiology of DSM-III-R bipolar I disorder in a general population survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Improving clinical trials: American Society of Clinical Psychopharmacology recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The evaluation of different approaches to randomized clinical trials. Report on the 1987 MacArthur Foundation Network I Methodology Workshop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Methodology in psychiatric research. Report on the 1986 MacArthur Foundation Network I Methodology Institute.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Ultra-rapid and ultradian cycling in bipolar affective illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Not in our methods, but in our ignorance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Generalisability of results from randomised drug trials. A trial on antimanic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Assessment of Agents for the Treatment of Head Injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Is there a lithium withdrawal syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Reduced mortality of manic-depressive patients in long-term lithium treatment: an international collaborative study by IGSLI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Ethics and practice: alternative designs for phase III randomized clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Randomized trials or observational tribulations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Special issues in trial design and use of placebo in bipolar illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Beyond lithium in the treatment of bipolar illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

New Designs for Studies of the Prophylaxis of Bipolar Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Statistical approaches to trial durations in episodic affective illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Methodological issues in developing new acute treatments for patients with bipolar illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Planning group sizes in clinical trials with a continuous outcome and repeated measures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Bipolar II: the most common bipolar phenotype?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The Stanley Foundation Bipolar Treatment Outcome Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900057-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3956(02)00057-2

1 reference

5 August 2017

1 reference